EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY-NC 4.0

Utility of pleural fluid biomarkers in differentiating malignant and benign pleural effusion: a cross-sectional study

Nishant Kumar Chauhan, Yogendra Singh Rathore, Mithu Banerjee, Naveen Dutt, Gopal Durgeshwar, Iyer Hariharan

Monaldi Archives for Chest Disease · 06.08.2026

DOI: 10.4081/monaldi.2026.3731 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Monaldi Archives for Chest Disease, online erschienen am 06.08.2026. Verfasst von Nishant Kumar Chauhan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, All India Institute of Medical Sciences, Jodhpur. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As cytopathological examination of the pleural fluid (PF) has a low yield, it is difficult to differentiate benign from malignant pleural effusions (PEs). There is still a lack of biomarkers in PF that can reliably help in diagnosing malignant PEs. Diagnostic accuracy in diagnosing malignant PEs is enhanced by the presence of tumor markers in PE. This would raise the likelihood of diagnosing malignant PEs with an unclear cause and starting treatment interventions early to lower morbidity and death rates in the patient. Thus, in an effort to enhance the PE diagnosis, novel PF biomarkers such as cancer ratio, cancer ratio plus, carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), and calprotectin were evaluated. A total of 108 patients with PEs were taken, and after applying inclusion and exclusion criteria, 83 patients with exudative PE were evaluated. After clinical history and routine blood investigations, PF was sent for cytopathology, biochemical examinations, microbiological examinations for aerobic culture, fungal culture, mycobacterial culture, and biomarker (CEA, CA-125, calprotectin) analyses. Out of 83 patients with exudative PE, malignant effusion was diagnosed in 40 patients, while 43 had benign effusions. PF biomarkers adenosine deaminase (ADA), CEA, cancer ratio, calprotectin, age/ADA and serum lactate dehydrogenase (LDH)/calprotectin ratio showed a statistically significant (p

Schlagwörter

Stichwörter der Autor:innen

BiomarkersCEAcalprotectincancer ratiopleural effusion

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, All India Institute of Medical Sciences, Jodhpur.
  • Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur.

Zitieren

APA

Chauhan, N. K., Rathore, Y. S., Banerjee, M., Dutt, N., Durgeshwar, G., & Hariharan, I. (2026). Utility of pleural fluid biomarkers in differentiating malignant and benign pleural effusion: a cross-sectional study. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2026.3731

Vancouver

Chauhan NK, Rathore YS, Banerjee M, Dutt N, Durgeshwar G, Hariharan I. Utility of pleural fluid biomarkers in differentiating malignant and benign pleural effusion: a cross-sectional study. Monaldi Archives for Chest Disease. 2026. doi:10.4081/monaldi.2026.3731

BibTeX
@article{Chauhan2026,
  author = {Chauhan, Nishant Kumar and Rathore, Yogendra Singh and Banerjee, Mithu and Dutt, Naveen and Durgeshwar, Gopal and Hariharan, Iyer},
  title = {Utility of pleural fluid biomarkers in differentiating malignant and benign pleural effusion: a cross-sectional study},
  journal = {Monaldi Archives for Chest Disease},
  year = {2026},
  doi = {10.4081/monaldi.2026.3731}
}
Kostenlos starten →